Literature DB >> 6441522

Hepatitis B or non-A, non-B virus infection in multitransfused thalassaemic patients.

G A Moroni, G Piacentini, S Terzoli, G Jean, G Masera.   

Abstract

We undertook a four year study of 128 thalassaemic patients who had undergone several transfusions, to determine the incidence of hepatitis B virus markers and the activities of transaminases in their sera each month. The results showed that the possibility of these patients contracting hepatitis B virus infection is still high, although on only one occasion was a transient antigenaemia found, indicating low viral replication. Furthermore, the probability of contact with hepatitis B virus increases with the number of transfusions and, therefore, with age. About 25% of these patients were positive for hepatitis B markers and 80% for other hepatitis markers including the case of cytomegalovirus hepatitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6441522      PMCID: PMC1628898          DOI: 10.1136/adc.59.12.1127

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  14 in total

1.  Post-transfusion hepatitis in Italy.

Authors:  F Tremolada; G Realdi; F Noventa; A Alberti; E Pornada; C Valfre; V Gallucci
Journal:  Lancet       Date:  1982-04-10       Impact factor: 79.321

2.  Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study.

Authors:  Y E Cossart; S Kirsch; S L Ismay
Journal:  Lancet       Date:  1982-01-23       Impact factor: 79.321

3.  The incidence of hepatitis-associated antigen and antibody in patients with thalassaemia in Greece.

Authors:  J Economidou; M Constantoulakis; O Augustaki; P E Taylor; A J Zuckerman; P M Baines; M A Bryceson
Journal:  Vox Sang       Date:  1970 Sep-Oct       Impact factor: 2.144

4.  Role of chronic hepatitis in development of thalassaemic liver disease.

Authors:  G Masera; G Jean; G Gazzola; M Novakova
Journal:  Arch Dis Child       Date:  1976-09       Impact factor: 3.791

5.  Cirrhosis associated with multiple transfusions in thalassaemia.

Authors:  G Jean; S Terzoli; R Mauri; L Borghetti; A Di Palma; A Piga; M Magliano; M Melevendi; M Cattaneo
Journal:  Arch Dis Child       Date:  1984-01       Impact factor: 3.791

6.  Serologic evidence of hepatitis A and B virus infections in thalassemia patients: a retrospective study.

Authors:  C E Stevens; J A Silbert; D R Miller; J L Dienstag; R H Purcell; W Szmuness
Journal:  Transfusion       Date:  1978 May-Jun       Impact factor: 3.157

7.  Sequential study of liver biopsy in thalassaemia.

Authors:  G Masera; G Jean; V Conter; S Terzoli; R A Mauri; M Cazzaniga
Journal:  Arch Dis Child       Date:  1980-10       Impact factor: 3.791

8.  Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.

Authors:  G Realdi; A Alberti; M Rugge; A M Rigoli; F Tremolada; L Schivazappa; A Ruol
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

9.  Antibody to hepatitis B core antigen in blood donors with a history of hepatitis.

Authors:  E Tabor; J H Hoofnagle; L F Barker; G Pineda-Tamondong; N Nath; L A Smallwood; R J Gerety
Journal:  Transfusion       Date:  1981 May-Jun       Impact factor: 3.157

10.  Prevalence of hepatitis A and B infections in multiply transfused thalassaemic patients.

Authors:  G Papaevangelou; G Frösner; J Economidou; S Parcha; A Roumeliotou
Journal:  Br Med J       Date:  1978-03-18
View more
  2 in total

1.  Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major.

Authors:  B Wonke; A V Hoffbrand; D Brown; G Dusheiko
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

2.  Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.

Authors:  M A Aldouri; B Wonke; A V Hoffbrand; D M Flynn; M Laulicht; L A Fenton; P J Scheuer; C C Kibbler; C A Allwood; D Brown
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.